List of Excipients in Branded Drug IBUPROFEN SODIUM

Generic Drugs Containing IBUPROFEN SODIUM

Company	Ingredient	NDC	Excipient
Walgreen Company	ibuprofen	0363-0909	FD&C BLUE NO. 2
Walgreen Company	ibuprofen	0363-0909	FD&C YELLOW NO. 6
Walgreen Company	ibuprofen	0363-0909	FERRIC OXIDE YELLOW
Walgreen Company	ibuprofen	0363-0909	GLYCERYL MONOSTEARATE

What are the Most Frequently-Used Excipients in IBUPROFEN SODIUM?

# Of NDCs	Excipient
1	FD&C BLUE NO. 2
1	FD&C YELLOW NO. 6
1	FERRIC OXIDE YELLOW
1	GLYCERYL MONOSTEARATE

Ibuprofen Sodium Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Ibuprofen sodium is a salt-form strategy for improving aqueous dissolution and enabling liquid or injectable dosage forms. Its strongest commercial opportunities are rapid-release oral products, pediatric liquids, effervescent sachets, and hospital formulations. The principal development risks are hygroscopicity, sodium exposure, taste, pH control, gastrointestinal tolerability, and limited differentiation from low-cost ibuprofen products.

What is ibuprofen sodium and how does it differ from ibuprofen?

Ibuprofen sodium is the sodium salt of ibuprofen, a propionic-acid nonsteroidal anti-inflammatory drug. It contains the same pharmacologically active ibuprofen moiety as free-acid ibuprofen but has different physicochemical properties.

Attribute	Ibuprofen free acid	Ibuprofen sodium
Drug class	NSAID	NSAID salt
Molecular weight	About 206.28 g/mol	About 228.26 g/mol for anhydrous salt
Aqueous behavior	Poorly water-soluble acid	Improved apparent aqueous solubility
Typical dosage forms	Tablets, capsules, suspensions, gels	Rapid-release tablets, solutions, suspensions, effervescent products, injectables
Sodium contribution	None from active ingredient	About 10.1% of salt mass
Regulatory position	Established OTC and prescription ingredient	Product-specific regulatory assessment
Primary value proposition	Low cost and broad familiarity	Faster dissolution and formulation flexibility

The salt does not automatically create faster clinical absorption. It can reduce the dissolution barrier, but pharmacokinetic benefit depends on particle size, excipient selection, tablet disintegration, gastric conditions, dose, and whether the product is taken with food.

Ibuprofen sodium should be distinguished from ibuprofen lysine and ibuprofen arginine. Those are separate salts with different molecular weights, manufacturing requirements, regulatory records, and patent positions.

What excipient strategy best supports ibuprofen sodium?

The excipient strategy should be selected by dosage form rather than by salt status alone. For immediate-release products, the target is rapid wetting, breakup, and dissolution without excessive moisture exposure. For liquids, the target is chemical stability, acceptable taste, and controlled pH. For injectables, the target is sterility, particulate control, osmolality, and container compatibility.

Immediate-release tablets and capsules

A practical tablet architecture uses:

• A highly soluble or directly compressible diluent
• A superdisintegrant
• A low-level wetting agent where needed
• A dry binder
• A glidant
• A lubricant compatible with rapid dissolution
• A moisture-barrier coating or package

Potential excipient classes include microcrystalline cellulose, mannitol, lactose, silicified microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, crospovidone, colloidal silicon dioxide, and magnesium stearate.

The main development issue is balancing compression strength against disintegration. Excessive hydrophobic lubricant or over-compression can slow dissolution, eliminating the advantage of the salt. Crospovidone is often attractive where rapid capillary uptake is needed. Croscarmellose sodium and sodium starch glycolate can provide strong swelling but require control of tablet hardness and moisture.

Mannitol can improve mouthfeel in chewable or orally disintegrating products. It is less hygroscopic than several alternative polyols but can require formulation work to achieve robust tablet tensile strength. Lactose may be economical but requires assessment for compatibility, particularly in formulations containing reactive impurities or high residual moisture.

Effervescent tablets and sachets

Ibuprofen sodium is well suited to effervescent concepts because it can support aqueous dispersion without relying entirely on the dissolution of free-acid ibuprofen. The formulation must control acid-base reaction during manufacture and storage.

Relevant excipient systems include citric acid, tartaric acid, sodium bicarbonate, potassium bicarbonate, and polyol-based fillers. Key controls are:

• Low water activity
• Dry-room processing
• Moisture-resistant foil packaging
• Granule particle-size control
• Carbon dioxide release rate
• Final drink pH
• Sodium load per dose

A sodium-containing effervescent system can produce a materially higher sodium burden than the active ingredient alone. A potassium-based buffer may reduce sodium contribution, but it introduces potassium exposure and separate labeling considerations.

Oral liquids and pediatric products

Ibuprofen sodium can support clear or less turbid oral liquids, but solubilization does not eliminate taste challenges. The active ingredient has a characteristic bitter and acidic taste profile. The formulation may require a combination of sweetener, flavor, taste-masking polymer, and viscosity modifier.

Useful excipient categories include:

• Sucrose, sorbitol, glycerin, or maltitol as sweetening and bulking agents
• Sucralose or acesulfame potassium for reduced-sugar products
• Xanthan gum, hydroxyethylcellulose, or sodium carboxymethylcellulose for viscosity
• Citrate or phosphate buffers
• Polysorbate 80 or another compatible wetting agent
• Preservatives such as sodium benzoate or potassium sorbate, where justified
• Chelating agents such as disodium edetate when metal-catalyzed degradation is a concern

Pediatric formulations should avoid unnecessary sodium, sugar, ethanol, and propylene glycol exposure. The sodium content should be calculated per dose and displayed where required by the target market. A 200 mg ibuprofen-equivalent dose of anhydrous ibuprofen sodium contributes approximately 22 mg of sodium based on stoichiometry. Hydrated material may have a different salt assay and mass basis.

Injectable formulations

The commercial precedent for intravenous ibuprofen is Caldolor, marketed by Cumberland Pharmaceuticals. The FDA labeling identifies ibuprofen injection for adult and pediatric indications and describes dilution before administration. The commercial formulation uses arginine and other excipients to maintain solution characteristics and tolerability rather than relying on a simple oral-tablet excipient system (U.S. Food and Drug Administration, 2024a).

An injectable ibuprofen sodium program requires control of:

• Solution pH
• Osmolality
• Buffer capacity
• Particulate matter
• Sterility assurance
• Extractables and leachables
• Container closure integrity
• Infusion-site tolerability
• Dilution compatibility with common intravenous fluids

Arginine may assist solubilization and pH control, but its use also affects osmolality and compatibility. Phosphate buffers can create precipitation risks with certain cations and should be evaluated across dilution conditions. The development package must address terminal sterilization versus aseptic processing, light exposure, and stability after dilution.

What formulations are protected by ibuprofen sodium patents?

The core ibuprofen molecule is an old active ingredient, and basic composition-of-matter exclusivity is no longer available. Commercially relevant protection therefore tends to focus on:

• Specific salt forms
• Hydrates or polymorphs
• Particle-size distributions
• Rapid-release formulations
• Injectable solutions
• Pediatric liquids
• Effervescent compositions
• Combination products
• Manufacturing processes
• Stability-improving packaging
• Specific dosing regimens or clinical uses

Salt and formulation claims can be commercially meaningful if they produce a measurable pharmaceutical benefit and are supported by comparative data. Claims covering routine excipient substitution are generally more vulnerable than claims tied to defined dissolution, stability, impurity, or delivery performance.

For a new ibuprofen sodium product, the strongest filing strategy is usually a layered portfolio:

Patent layer	Commercial purpose	Relative strength
Salt, hydrate, or polymorph	Controls drug-substance supply and solid form	Moderate if technically distinct
Composition claim	Protects defined excipient ratios or dosage form	Moderate
Dissolution or performance claim	Links formulation to measurable release	Moderate to strong if reproducible
Injectable solution	Protects pH, concentration, buffer, and stability	Stronger when technically narrow
Manufacturing process	Protects crystallization, drying, or granulation	Variable
Method of use	Protects selected dosing or administration	Usually narrower
Packaging system	Protects moisture and stability controls	Narrow but commercially useful

The filing date is critical. A formulation patent generally has a 20-year term from the earliest effective nonprovisional filing date, subject to patent-term adjustment or extension under applicable law (U.S. Patent and Trademark Office, 2024).

What is the Orange Book status of ibuprofen sodium?

Ibuprofen is an established small-molecule active ingredient with extensive OTC use and prescription products. It does not qualify for new chemical entity exclusivity merely because the active ingredient is presented as a sodium salt.

The FDA Orange Book is product-specific. It lists approved products, therapeutic equivalence codes, patents submitted by NDA holders, and regulatory exclusivity. A sponsor should review the current Orange Book entries for the specific ibuprofen sodium NDA, injectable product, combination product, or 505(b)(2) product rather than infer status from the active ingredient alone (U.S. Food and Drug Administration, 2024b).

For a new ibuprofen sodium product:

• A standard generic pathway may be available if the reference product, dosage form, route, strength, and equivalence requirements align.
• A 505(b)(2) application may be more appropriate for a new salt, injectable presentation, liquid, or delivery system.
• FDA acceptance of the salt form does not guarantee automatic therapeutic equivalence to free-acid ibuprofen.
• Orange Book patent listing depends on the NDA holder and the scope of the approved labeling.
• OTC monograph reliance may be available for qualifying ibuprofen products, but a novel salt, dosage form, or indication can require a separate regulatory strategy.

When does ibuprofen sodium lose exclusivity?

Ibuprofen itself has no remaining basic molecule exclusivity in the United States. Commercial exclusivity for an ibuprofen sodium product depends on product-specific patents, regulatory exclusivity, and market access barriers.

Exclusivity type	Relevance to ibuprofen sodium
New chemical entity exclusivity	Generally unavailable for an old active ingredient
New clinical investigation exclusivity	Possible only if statutory requirements are met
Orphan-drug exclusivity	Unlikely for conventional ibuprofen indications
Formulation patents	Potentially relevant
Salt or polymorph patents	Potentially relevant
Method-of-use patents	Relevant only to defined approved indications
Trade secrets	Relevant to process yield, impurity control, and scale-up
Regulatory know-how	Relevant to injectable and pediatric products

The practical loss of exclusivity may occur before patent expiration if a competitor can design around the claim, use a different salt, rely on free-acid ibuprofen, or launch under an OTC pathway.

Which companies are challenging ibuprofen sodium products?

The competitive field is fragmented. It includes multinational OTC companies, generic manufacturers, hospital injectable suppliers, contract development and manufacturing organizations, and private-label retailers.

The principal competitive products are not limited to ibuprofen sodium. They include:

• Conventional ibuprofen tablets and capsules
• Ibuprofen lysine products
• Ibuprofen arginine products
• Ibuprofen oral suspensions
• Ibuprofen intravenous injection
• Acetaminophen products
• Naproxen products
• Ketorolac injection in hospital settings

Major global ibuprofen participants include companies associated with Advil, Motrin, Nurofen, Brufen, and generic ibuprofen products. Market entry competition is primarily based on price, retailer placement, dosage-form convenience, hospital contracting, and supply reliability rather than broad patent exclusivity.

Publicly available information does not establish a single, unified Paragraph IV campaign directed specifically at an ibuprofen sodium reference product. Paragraph IV risk must be assessed at the individual NDA and patent-listing level. A challenger could target a formulation, salt, method-of-use, or process patent even where free-acid ibuprofen is widely available.

What generic entry risks exist for ibuprofen sodium?

Generic entry risk is high for ordinary oral products and more moderate for technically demanding dosage forms.

High-risk segments

Conventional immediate-release tablets and capsules face:

• Low active-ingredient cost
• Numerous established suppliers
• Broad consumer familiarity
• Limited clinical differentiation
• Easy substitution with free-acid ibuprofen
• Retailer pressure on price

Moderate-risk segments

Pediatric liquids and chewables may retain more commercial defensibility because of flavor, dosing accuracy, viscosity, packaging, and palatability. These attributes are difficult to protect broadly but can support brand preference.

Lower near-term substitution risk

Sterile injectable products have higher barriers because competitors must demonstrate sterile manufacturing, stability, dilution compatibility, container closure integrity, and hospital supply reliability. Those barriers are commercial and technical rather than necessarily patent-based.

How strong is the ibuprofen sodium patent estate?

The estate is strongest when the product delivers a defined technical result that free-acid ibuprofen does not readily provide. Examples include:

• Stable high-concentration aqueous injection
• Controlled impurity profile during manufacture
• Rapid dissolution under defined test conditions
• Improved stability in a low-moisture oral dosage form
• A reproducible solid form with manufacturing advantages
• A clinically useful low-volume pediatric liquid

The estate is weaker when claims rely on broad categories of conventional excipients or routine salt selection. A formulation patent covering "ibuprofen sodium with a disintegrant and lubricant" may face substantial design-around risk unless the claim includes a narrow and unexpected performance profile.

What licensing deals and manufacturing barriers matter?

Ibuprofen sodium is unlikely to require a license to the basic API. Licensing value is more likely to arise from:

• A proprietary injectable platform
• A taste-masking technology
• A high-throughput effervescent manufacturing process
• A stable amorphous or crystalline salt form
• A pediatric dosing device
• A hospital distribution or private-label agreement
• A contract manufacturing relationship with validated sterile capacity

Manufacturing barriers include salt crystallization control, residual solvent limits, water activity, particle-size distribution, blend uniformity, and impurity management. For injectables, sterile fill-finish capacity and validated container systems may be more decisive than patent ownership.

API sourcing is also a potential risk. A sponsor should qualify more than one supplier where possible and confirm that each supplier can control salt stoichiometry, hydration state, polymorphism, residual solvents, elemental impurities, and nitrosamine-related risk where applicable.

What commercial opportunities exist for ibuprofen sodium?

The best opportunities are dosage-form and channel specific.

Opportunity	Rationale	Key barrier
Rapid-release oral tablets	Consumer demand for fast onset and convenience	Need credible dissolution and clinical differentiation
Pediatric liquid	Salt can support aqueous formulation	Taste, sodium, preservative, and dosing-device control
Effervescent sachets	Convenient dispersed dose and portability	Moisture protection and sodium exposure
Orally disintegrating tablets	Useful where swallowing is difficult	Taste masking and tablet robustness
IV hospital product	Higher technical and manufacturing barrier	Sterility, compatibility, and hospital contracting
Low-sugar liquid	Supports diabetic or reduced-sugar positioning	Palatability and preservative system
Combination analgesic	Differentiates from standard ibuprofen	Combination-product regulatory and safety requirements
Private-label products	Retailer demand for differentiated formats	Price compression and supply reliability

The most defensible commercial proposition is not simply "ibuprofen sodium." It is a defined product benefit supported by dissolution, onset, palatability, dosing convenience, or hospital utility.

How does ibuprofen sodium compare with ibuprofen lysine?

Factor	Ibuprofen sodium	Ibuprofen lysine
Salt counterion	Sodium	Lysine
Sodium exposure	Present	Lower sodium contribution from active salt
Oral liquid potential	Strong	Strong
Taste profile	Requires masking	Requires masking
Injectable precedent	Product-specific	Established in some markets and formulations
Differentiation	Dissolution and formulation flexibility	Dissolution, tolerability, and existing product precedent
Patient positioning	Less attractive for sodium-restricted users	May be preferable where sodium reduction matters
Patent strategy	Salt, formulation, process	Salt, formulation, process

Counterion selection should be based on the intended route, target patient, pH range, stability, dose, and label burden. Sodium may be commercially acceptable in a low-dose oral product but less attractive for repeated high-dose therapy or sodium-sensitive populations.

What FDA regulatory pathway applies?

The regulatory pathway depends on the proposed product:

• A conventional OTC oral product may rely on the applicable OTC monograph if all conditions are met.
• A prescription oral product may require an ANDA if a suitable reference product exists.
• A new salt, liquid, injectable, or delivery system may require a 505(b)(2) application.
• A hospital injectable must satisfy current good manufacturing practice, sterility, stability, and labeling requirements.
• A product with a new indication requires clinical support appropriate to the claim.

FDA labeling for ibuprofen products emphasizes dose limits, gastrointestinal bleeding, cardiovascular risk, renal effects, hypersensitivity, and pregnancy-related risks. A sodium-containing formulation also requires a quantitative sodium assessment for labeling and clinical positioning (U.S. Food and Drug Administration, 2024a; U.S. Food and Drug Administration, 2015).

Key Takeaways

• Ibuprofen sodium is primarily a formulation-enabling salt, not a new active pharmaceutical entity.
• The strongest opportunities are rapid-release oral products, pediatric liquids, effervescent formats, orally disintegrating tablets, and sterile injectables.
• Excipient selection should prioritize dissolution, moisture control, taste masking, pH stability, and sodium exposure.
• Core ibuprofen molecule exclusivity is expired; commercial protection must come from salt, formulation, manufacturing, packaging, or use claims.
• Generic risk is high for ordinary tablets and capsules, but technical barriers are greater for pediatric and injectable products.
• The commercial case must demonstrate a measurable product advantage over low-cost ibuprofen free acid and established ibuprofen salt products.

Frequently Asked Questions

Is ibuprofen sodium more effective than regular ibuprofen?

Ibuprofen sodium may dissolve faster, but greater dissolution speed does not automatically establish superior clinical efficacy. Comparative pharmacokinetic or clinical data are needed to support a faster-onset claim.

Does ibuprofen sodium contain more sodium than ordinary ibuprofen?

Yes. The salt contributes sodium from the counterion. A 200 mg ibuprofen-equivalent dose contains approximately 22 mg of sodium based on the anhydrous molecular-weight relationship.

Can ibuprofen sodium be sold as an OTC product?

Potentially, depending on the dosage form, strength, labeling, manufacturing controls, and applicable FDA monograph requirements. A novel salt or delivery system may require an NDA or 505(b)(2) pathway.

Is ibuprofen sodium suitable for injectable development?

Yes, but injectable development requires sterile manufacturing, pH and osmolality control, dilution compatibility, particulate testing, and container-closure validation. The technical burden is materially higher than for oral tablets.

Are ibuprofen sodium products exposed to biosimilar competition?

No. Ibuprofen sodium is a small-molecule drug and is not regulated through the biosimilar pathway. Competition would arise through generic, hybrid, OTC, or competing branded products.

References

1. U.S. Food and Drug Administration. (2015). Nonsteroidal anti-inflammatory drugs: Drug safety communication and labeling information. FDA.

2. U.S. Food and Drug Administration. (2024a). Caldolor (ibuprofen injection) prescribing information. Cumberland Pharmaceuticals, Inc.

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024c). FDA guidance for industry: Applications covered by section 505(b)(2). FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Ibuprofen monograph. USP.

6. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension provisions. USPTO.